| Autor: |
Gusarov, D., Sokolova, I., Gusarova, V., Evteeva, E., Vorob'eva, T., Kosarev, S., Shibanova, E., Bairamashvili, D. |
| Předmět: |
|
| Zdroj: |
Pharmaceutical Chemistry Journal; Jul2012, Vol. 46 Issue 4, p234-240, 7p, 1 Diagram, 1 Chart, 4 Graphs |
| Abstrakt: |
Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not produced in the Russian Federation and must be imported from abroad. It was shown that H1-type histones with activities similar to that of Rituximab can be used for such therapy. We have developed an pilot-scale technology for the production of recombinant N, N- bis-met-histone H1.3. The activity and purity of the obtained preparation were demonstrated in several tests. The produced amount of active pharmaceutical ingredient was sufficient to start clinical trials in Russia. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
